Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma

Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy: Equality Impact Assessment - guidance development

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: final appraisal determination 2 information

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: final appraisal determination 2 document

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: final appraisal determination 2 document (PDF 417 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: evaluation report 2 information

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appraisal consultation 2

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appraisal consultation document information

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: evaluation report information

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appraisal consultation

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appraisal consultation document information

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: evaluation report

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: pre-meeting briefing

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: pre-meeting briefing (PDF 552 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Evidence Review Group report

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Evidence Review Group report (PDF 2.91 MB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Evidence Review group report - factual accuracy check

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Evidence Review group report - factual accuracy check (PDF 65 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: erratum to the ERG report

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: erratum to the ERG report (PDF 138 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Cell Therapeutics

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Cell Therapeutics (PDF 1.74 MB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: clarification

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: NICE clarification letter

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: NICE clarification letter (PDF 113 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Cell Therapeutics response to the NICE clarification letter

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Cell Therapeutics response to the NICE clarification letter (PDF 331 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appendix to manufacturer's clarification response

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appendix to manufacturer's clarification response (PDF 1022 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: patient group, professional group and NHS organisation submission statements

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Lymphoma Association

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Lymphoma Association (PDF 44 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: The Royal College of Physicians

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: The Royal College of Physicians (PDF 45 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: expert written personal statements

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: McMillan

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: McMillan (PDF 27 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Pettengell

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Pettengell (PDF 27 KB)

Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: Wilson

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): NICE's response to consultees and commentator comments on the draft scope and provisional matrix

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): final scope

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): final matrix

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): final matrix (superseded)

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): final scope (superseded)

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): NICE response to comments on draft scope (superseded)

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): draft scope

Lymphoma (non-Hodgkin's, relapsed, refactory) - pixantrone (monotherapy): provisional matrix